ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. - Wikidata - awgldk - TriplyDB

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

http://www.wikidata.org/entity/Q34583477

about

The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment Progress and prospects in pharmacogenetics of antidepressant drugs.P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures.Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics.Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.The ABCB1 transporter gene and antidepressant response.Pharmacogenetics of antidepressant response.Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.Pharmacogenetics of antidepressants The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians.The promise and reality of pharmacogenetics in psychiatry Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics.Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report.Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients.ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.Pharmacogenetics in psychiatry: are we ready for widespread clinical use?Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects Mechanisms of antidepressant resistance DNA variations in human and medical genetics: 25 years of my experience.Predicting potentially functional SNPs in drug-response genes.Pharmacogenetics of antidepressant response: an update Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.Psychotropic drug-drug interactions involving P-glycoprotein.Do we need pharmacogenetics to personalize antidepressant therapy?Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study.Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

P2860

Q26741187-04E22386-A053-45DE-83E9-8771D25745B3 Q26996411-A5257601-849B-4F89-91D3-0AA1360D1378 Q27015830-80292FEB-9DD4-498A-A3FF-A1EDDFF6028A Q30249569-B712A6B0-B626-42B7-9ED0-DC4B465B3954 Q30544869-E692AB43-F28F-4EDB-B3AD-F623BA104AAC Q33404025-FC4D96D5-DF28-48A6-8FB2-9532DB1C8211 Q33613526-95D2C63C-EF89-415A-83B9-D0D877734F0B Q33664684-447C03CF-6D00-49F0-A1F2-15654D7B8706 Q34062379-A1F0FFE8-9B2C-4141-9178-84B52C7B6022 Q34155796-4A807C90-1192-4E2C-8AC4-6837B875B407 Q34424865-AB2B1507-33CD-48D8-B9B4-907CA45A3F56 Q34871885-351C205A-017B-455B-9C71-EDD079E4BAC7 Q35026088-0DD46582-D8B2-4501-8FBA-4F4FDCED7C78 Q35085937-FE9816F4-855D-4827-9261-7FBEE794E62C Q35226451-920D6A6F-B59F-4505-ABCC-FFD4E0244D27 Q35653883-C36064A6-CD30-4885-8857-2DB9CABDEC9F Q35708089-AE1E1B0E-28E6-4950-8A88-F78424E37F1D Q35965584-F06B364C-8E26-4380-BA44-C326F43DCE19 Q36079358-A5334288-568A-4960-9BED-665172C6D6C7 Q36159042-09396E9A-EC80-49D5-A315-3E0B07D53C41 Q36323164-9623593E-8449-4399-9632-6B36D7B88795 Q36325439-342EB5B6-D907-4793-ACED-146107FF9B5A Q36591193-6E8AE058-E5D5-4D0F-99AE-B083C1994326 Q37076472-35F723B4-2CDF-4690-AF5A-854798894D3A Q37253554-D86BAE8E-26FB-4224-A535-F55AA2E7DAA9 Q37254054-9BB9E071-B6E9-4C75-B786-58E8291F72F4 Q37334088-506ABBB8-B7A9-4D8C-B639-9BC2A9BFB6CD Q37374228-0F5A1081-2043-428F-BFF8-2F0BCF66FC98 Q37448909-8FEFC361-44ED-4774-9D7F-C57F8D729F8E Q37464458-2F43BF07-4BA6-422B-B839-6E091575BE94 Q37808483-7C3ABA5E-A7AA-49FC-95D0-55956DEE2C5D Q37989490-BB6900A8-500C-4CB2-AE24-2928E1AF7850 Q38047816-E24AF82F-6B79-4B90-97B5-21C0D38C9741 Q38070163-4B787A24-F3F4-4BEE-ABCD-CDB3FA63BA1F Q38121519-C1FD9710-BC40-47CE-B8E7-AB9A17799D8B Q38414396-3D54A8A2-FE3D-46BB-A26B-E818330AF54C Q38453405-B1537663-8089-41CE-B8FA-732A6C863AD9 Q38484370-93A2794F-44BE-42F0-9B0C-E384BF049F95 Q38570611-E5447C21-0F41-477E-87CA-8820BCAFDB86 Q38983579-8798141A-28AC-444A-87F0-EA758F390EF0

P2860

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

http://www.wikidata.org/entity/Q34583477

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

ABCB1 (MDR1) gene polymorphism ...... ith major depressive disorder.

@ast

ABCB1 (MDR1) gene polymorphism ...... ith major depressive disorder.

@en

type

label

ABCB1 (MDR1) gene polymorphism ...... ith major depressive disorder.

@ast

ABCB1 (MDR1) gene polymorphism ...... ith major depressive disorder.

@en

prefLabel

ABCB1 (MDR1) gene polymorphism ...... ith major depressive disorder.

@ast

ABCB1 (MDR1) gene polymorphism ...... ith major depressive disorder.

@en

P1433

Q34583477-286784E2-945A-4CF6-AF09-8EF5285AE4C1

P1476

Q34583477-3C952EAA-03BD-45E5-9FF8-0AFA9C9C8367

P2093

Q34583477-1745F951-3115-46BE-86DE-3876BCE11B62

Q34583477-23C716C3-0B7C-4B88-B0B3-0E6BFD31E614

Q34583477-253BFDC2-D7BF-4B2F-96A6-CB75109E5465

Q34583477-50E18D1D-3844-4640-9F19-2A79190FA18A

Q34583477-658ABC3F-F9E0-4EB0-B506-2558EB2B4BC8

Q34583477-6D74C686-4EDB-446C-9732-845DEDB5F50B

Q34583477-7E66B7A2-9DE5-4031-A38C-8395945A8612

Q34583477-9FE3F713-788F-4C14-B362-2A7564754116

Q34583477-EB682661-1F9A-44A2-8FBF-8AD17EB725E0

P304

Q34583477-0D7E95D4-9647-4137-AF55-613CECCD83D9

P31

Q34583477-C481D8B8-9D70-4DAA-889C-A948FC5CF990

P356

Q34583477-8274E0E5-B042-4FCA-9EF7-B2996B891452

P433

Q34583477-3743C773-09FF-44ED-8DB6-EEEDE470C7DB

P478

Q34583477-FAFF167C-4926-4DCA-B264-DC9873B22505

P50

Q34583477-4049015A-08B6-43C3-B24E-4D2C4F8F8DE5

Q34583477-FB836856-448F-491A-B166-592313546763

P577

Q34583477-725135A8-CC52-4C9B-80AB-8FB6D55F0430

P698

Q34583477-F1DEEFBD-A043-41DF-B5E8-6002A2E560EE

P921

Q34583477-C38DCF09-E630-4F70-BB07-93DA376A8F55

P356

J.PNPBP.2007.09.003

P1433

Progress in Neuro-Psychopharmacology & Biological Psychiatry

P1476

ABCB1 (MDR1) gene polymorphism ...... with major depressive disorder

@en

P2093

Gaku Okugawa

http://www.w3.org/2001/XMLSchema#string

Junichi Azuma

http://www.w3.org/2001/XMLSchema#string

Laura Mandelli

http://www.w3.org/2001/XMLSchema#string

Masataka Wakeno

http://www.w3.org/2001/XMLSchema#string

Toshihiko Kinoshita

http://www.w3.org/2001/XMLSchema#string

Tsuyoshi Fukuda

http://www.w3.org/2001/XMLSchema#string

Yoshiteru Takekita

http://www.w3.org/2001/XMLSchema#string

Yuka Hosoi

http://www.w3.org/2001/XMLSchema#string

Yuka Ikenaga

http://www.w3.org/2001/XMLSchema#string

P304

398-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PNPBP.2007.09.003

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Serretti

P577

2007-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17913323

http://www.w3.org/2001/XMLSchema#string

P921